Abagovomab

Drug Profile

Abagovomab

Alternative Names: ACA 125; Anti-idiotype ovarian cancer vaccine; MAb ACA 125; Monoclonal Anti-idiotype Antibody ACA125

Latest Information Update: 22 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CellControl Biomedical Laboratories
  • Developer Menarini
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 22 Jul 2015 Discontinued - Phase-III for Ovarian cancer in USA and European Union (SC)
  • 23 Jul 2013 Phase-III development appears to be ongoing for Ovarian cancer in US and European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top